Cyclic AMP and PKA: how can a lot of good come from the potentially bad? : editorial to: "phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus" by Y. Birnbaum et al.
Barbara
B
Huisamen
D000818:Animals; D000077407:Cilostazol; D000242:Cyclic AMP / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D058987:Phosphodiesterase 3 Inhibitors / Q000494:pharmacology*; D013777:Tetrazoles / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*
C570834:MK0626; D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D014230:Triazoles; D000242:Cyclic AMP; D000077407:Cilostazol